Atopic Dermatitis (AD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Atopic dermatitis (AD) is a chronic inflammatory skin condition that typically begins in early childhood, causing age-specific skin problems, dryness, and severe itching. This condition significantly impacts the quality of life and makes patients more prone to allergic diseases. Numerous studies have linked AD during infancy to the later development of asthma, allergic rhinitis, and food allergies. About 80% of AD patients experience one or both of these conditions. Additionally, 35% of children with AD have food allergies, and they are more likely to suffer from skin infections and keratoconjunctivitis compared to the general population. Common chronic comorbidities in children with AD include asthma, psychosocial disorders, visual impairment, limb anomalies, and developmental issues. These comorbidities are more prevalent in those with AD. This group's most frequent acute conditions are upper respiratory tract infections, otitis media, conjunctivitis, and pharyngitis.

·       Thelansis indicates that globally, AD affects 15%–20% of children and 1%–3% of adults. The prevalence of AD is increasing worldwide and varies by geographic location, with higher rates in industrialized, high-income countries compared to agriculture-based, low-income regions.

 

Thelansis’s “Atopic Dermatitis (AD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Atopic Dermatitis (AD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Atopic Dermatitis (AD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Atopic Dermatitis (AD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Atopic Dermatitis (AD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Atopic Dermatitis (AD), Atopic Dermatitis (AD) market outlook, Atopic Dermatitis (AD) competitive landscape, Atopic Dermatitis (AD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033